Differential gene expression profiles of invasive and non-invasive non-functioning pituitary adenomas based on microarray analysis

Françoise Galland, Ludovic Lacroix, Patrick Saulnier, Philippe Dessen, Geri Meduri, Michéle Bernier, Stéphane Gaillard, Jean Guibourdenche, Thierry Fournier, Daniéle Evain-Brion, Jean Michel Bidart, Philippe Chanson

    Résultats de recherche: Contribution à un journalArticleRevue par des pairs

    71 Citations (Scopus)

    Résumé

    Non-functioning pituitary adenomas (NFPAs) may be locally invasive. Markers of invasiveness are needed to guide patient management and particularly the use of adjuvant radiotherapy. To examine whether invasive NFPAs display a specific gene expression profile relative to non-invasive tumors, we selected 40 NFPAs (38 of the gonadotroph type) and classified them as invasive (n=22) or non-invasive (n=18) on the basis of magnetic resonance imaging and surgical findings. We then performed pangenomic analysis with the 44k Agilent human whole genome expression oligonucleotide microarray in order to identify genes with differential expression between invasive and non-invasive NFPAs. Candidate genes were then tested in qRT-PCR. Prediction class analysis showed that the expression of 346 genes differed between invasive and non-invasive NFPAs (P<0.001), of which 233 genes were up-regulated and 113 genes were down-regulated in invasive tumors. On the basis of Ingenuity networks and the degree of up- or down-regulation in invasive versus non-invasive tumors, 35 genes were selected for expression quantification by qRT-PCR. Overexpression of only four genes was confirmed, namely IGFBP5 (P=0.02), MYO5A (P=0.04), FLT3 (P=0.01), and NFE2L1 (P=0.02). At the protein level, only myosin 5A (MYO5A) immunostaining was stronger in invasive than in non-invasive NFPAs. Molecular signature allows to differentiate 'grossly' invasive from non-invasive NFPAs. The product of one of these genes, MYO5A, may be a useful marker of tumor invasiveness.

    langue originaleAnglais
    Pages (de - à)361-371
    Nombre de pages11
    journalEndocrine-Related Cancer
    Volume17
    Numéro de publication2
    Les DOIs
    étatPublié - 1 juin 2010

    Contient cette citation